Researchers at a top US cancer center are experimenting with a new approach to immunotherapy for pleural mesothelioma – with exciting results. The research was done at Memorial Sloan Kettering Cancer Center in New York and published in a recent issue of Cancer Discovery. The Phase I trial is the first to treat pleural mesothelioma patients with CAR-T cell therapy and the PD-1 blocker pembrolizumab (Keytruda). Although the trial was small, 83 percent of patients lived for more than a year. Some lived for nearly two. Malignant Mesothelioma commonly claims the lives of patients within months. This new type of immunotherapy for pleural mesothelioma could be a breakthrough in improving survival. The Challenge of Malignant Mesothelioma Scientists have known about … Continue reading CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma?
A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma patients. Keytruda is the brand name for pembrolizumab. It is an immunotherapy drug called an immune checkpoint inhibitor. It helps unmask mesothelioma cells so that the immune system can find and fight them. But the effectiveness of Keytruda is not consistent. Some patients respond well while others do not respond at all. The new study looked at how different people metabolize the drug. Understanding this could help doctors determine the best dose for each mesothelioma patient. Pembrolizumab and its Link to Mesothelioma Survival Malignant pleural mesothelioma is a deadly form of lung cancer. Asbestos exposure is the main cause of … Continue reading Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction
Results of the latest Keytruda study show the drug works well for a select few mesothelioma patients, but not well at all for most others. Keytruda is the brand name for pembrolizumab. It is a type of immunotherapy drug. Early studies suggested that Keytuda might offer real hope for people with the aggressive cancer, malignant pleural mesothelioma. But the latest Keytruda study shows most patients do not have lasting results with this treatment. That is especially true for patients whose cells do not express high levels of the protein PD-1. How the Latest Keytruda Study Worked Keytruda is an immunotherapy drug. It works by activating the immune system. Mesothelioma cells can use a protein called PD-1 to protect themselves from … Continue reading Latest Keytruda Study Shows Limited Results for Most Mesothelioma Patients
A new Australian study suggests that too many people are being left out of mesothelioma clinical trials under current trial rules. The researchers say that eligibility requirements around pleural mesothelioma studies are too strict. The result is that many people never have the opportunity to take advantage of investigational treatments only available through studies. In addition, the trial data gathered may not really apply to average mesothelioma patients. The Australian researchers are calling for changes that will let more people qualify for mesothelioma clinical trials. What Are Mesothelioma Clinical Trials? Pleural mesothelioma is an intractable cancer of the lining around the lungs. People who get it usually worked in an industry that exposed them to asbestos. Once asbestos gets in … Continue reading Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds
There’s more encouraging news about immunotherapy with Keytruda for people with pleural mesothelioma. The latest report comes from the University of Kansas School of Medicine. A doctor in the orthopaedic department at the school has malignant pleural mesothelioma. He and three colleagues recently published news of his “prompt and exceptionally favorable” response to firstline treatment with pembrolizumab. Pembrolizumab (Keytruda) is an immune checkpoint inhibitor. Several studies suggest that adding immunotherapy with Keytruda to other mesothelioma treatments may improve outcomes. But the new case report indicates that Keytruda could also be a good firstline option for some mesothelioma patients. How Immunotherapy with Keytruda Works Immunotherapy is a form of cancer treatment that uses the body’s immune system against the cancer. … Continue reading Immunotherapy with Keytruda for Mesothelioma: A New Case Report
Doctors in the UK have started treatment on the first patient in the trial of a new drug combination for relapsed mesothelioma. The drug is called bemcentinib. It blocks a protein encoded by the AXL gene. People with mesothelioma tend to overexpress this protein. Studies show that this extra AXL protein might help cancer cells hide from the immune system. It might also help them spread to other parts of the body. In the new trial, patients with relapsed mesothelioma will get a combination of bemcentinib and Keytruda (pembrolizumab). Keytruda is an immunotherapy drug. Like bemcentinib, it helps make mesothelioma cells vulnerable to immune system attack. Animal studies and tests in lung cancer patients show that bemcentinib may help immune … Continue reading First Patient Dosed in New Trial for Relapsed Mesothelioma
There is hope that a new lung cancer trial combining Keytruda and Tumor Treating Fields could lead to a new treatment for pleural mesothelioma. Recent studies show Keytruda (pembrolizumab) is one of the most promising immunotherapy drugs against malignant mesothelioma. Electrical device Tumor Treating Fields is only the second treatment to receive FDA approval for mesothelioma. This summer, the manufacturers of these two treatments announced they would team up. They will test Keytruda and Tumor Treating Fields in patients with non-small cell lung cancer. The results could impact the future of mesothelioma treatment, too. Two Promising Therapies: Keytruda Keytruda is an immunotherapy drug. It blocks a protein called PD-1. Many types of cancer cells overproduce PD-1 to evade the immune … Continue reading Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?
A combination of three powerful mesothelioma therapies could become a new first-line treatment for mesothelioma if an upcoming clinical trial is successful. The makers of the experimental immunotherapy drug ONCOS-102 announced the new clinical trial. It will enroll up to 100 mesothelioma patients from around the world. The trial will test ONCOS-102 along with Keytruda (pembrolizumab) and standard chemotherapy. Keytruda is an immune checkpoint inhibitor. Both ONCOS-102 and Keytruda have shown some promise when combined with mesothelioma chemotherapy. Targovax hopes that the triple therapy approach will produce an even more powerful first-line treatment for mesothelioma. Clinic Trial of ONCOS-102 A first-line treatment is a treatment for mesothelioma patients who have not yet had any other therapies. Most patients start with … Continue reading Triple Therapy May Become New First-Line Treatment for Mesothelioma
The FDA approval of Keytruda this month may help some patients in their battle against asbestos cancer. Keytruda is the brand name for the immunotherapy drug pembrolizumab. The FDA first approved Keytruda as a first-line treatment for metastatic non-small cell lung cancer. That initial approval came in 2017. The new FDA approval of Keytruda is for treatment of specific kinds of malignant tumors. Eligible patients must have unresectable mesothelioma and no other treatment options. How Keytruda Fights Mesothelioma Keytruda is an immune checkpoint inhibitor. It blocks a protein called PD-L1. Mesothelioma cells use PD-L1 to avoid immune system attack. Drugs like Keytruda unmask these hiding cells and make them more vulnerable to treatment. But not all patients with mesothelioma will … Continue reading FDA Approval of Keytruda will Help Some Mesothelioma Patients
Australian researchers are warning of some rare but deadly side effects of Opdivo (nivolumab) for pleural mesothelioma. They have just published a case report of a mesothelioma patient on nivolumab, a drug often used to treat lung cancer. The patient developed swelling of the heart and other muscles. The swelling lasted for months, even after they stopped taking the drug. The case report details the healthcare teams’ effort to manage these potentially lethal side effects of Opdivo. They caution that other immune checkpoint inhibitors might cause similar complications. How Opdivo Fights Mesothelioma The primary treatment for mesothelioma is chemotherapy with pemetrexed (Alimta). Eventually, most patients stop responding to chemotherapy. At that point, doctors may turn to an immunotherapy drug like … Continue reading Rare But Dangerous Side Effects of Opdivo for Mesothelioma